Trikafta 50-25-37.5 MG/75 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FCZD0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,854
Award facts
- Contract value 100% obligated
- $18,853.94 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,853.94 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 50-25-37.5 mg/75 mg tablets (84-count units). The award, issued on December 29, 2025, with an ultimate completion date of December 30, 2025, carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $499.9 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceuticals and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division, with its product portfolio encompassing branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The contractor's underlying indefinite delivery contract, awarded November 13, 2025, spans a 30-month base period with three 30-month option periods through December 31, 2036, positioning the company as a critical supplier for DoD military healthcare operations globally. No subcontractors have been identified in the award documentation, indicating direct fulfillment by the prime contractor.
Quick answers
Who was awarded contract SPE2DR26FCZD0?
SPE2DR26FCZD0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 29, 2025.
How much is contract SPE2DR26FCZD0 worth?
The government has obligated $18,854 on SPE2DR26FCZD0.
Is contract SPE2DR26FCZD0 an order under another contract?
Yes. SPE2DR26FCZD0 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZD0 competed?
The extent of competition for SPE2DR26FCZD0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award